JPM-MCS requests information on biological threat diagnostic devices

The Joint Project Management Office Medical Countermeasure Systems released a Request for Information on Thursday to companies involved in the domestic healthcare market for FDA-cleared diagnostics.

The JPM-MCS wants to collect information about systems that can be used with NGDS increment 1 sample-to-answer molecular diagnostic platform. The platform is used in combat support hospitals and ships. Information is requested for systems that can test patients before they exhibit symptoms or within 12 to 120 hours of showing symptoms.

Systems should be able to test for pathogenic bacteria, parasites, fungus, prions and biological toxins. The JPM-MCS requested that the systems be available for use in small clinical laboratories that provide centralized support, be HIPAA-compliant and provide non-invasive or low-invasive screening tools.

The JPM-MCS would like the offered systems to be portable, safe for use with BLS 4 agents, provide test results within 30 minutes, provide a permanent capture of data and have low complexity.

The office said the information request is for planning purposes and not a solicitation for proposals.

"Responses to this notice are not offers and cannot be accepted by the Government to form a binding contract," the office said in the RFI. "It is not to be construed as a commitment by the Government nor will the Government pay for the information solicited."